Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$111MLATEST DEAL AMOUNT
Provider of development stage biotechnology services for the treatment of inflammatory diseases. The company is developing therapies that regulate the complement system to treat inflammatory and immune diseases.